BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/2/2014 10:31:00 AM | Browse: 866 | Download: 778
Publication Name World Journal of Gastroenterology
Manuscript ID 5318
Country/Territory United States
Received
2013-08-29 09:12
Peer-Review Started
2013-08-29 16:28
To Make the First Decision
2013-12-16 17:48
Return for Revision
2013-10-16 11:14
Revised
2013-10-31 20:08
Second Decision
2014-01-20 16:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-20 18:02
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-02-27 21:30
Publish the Manuscript Online
2014-03-06 14:13
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Opioid growth factor and the treatment of human pancreatic cancer: A review
Manuscript Source Invited Manuscript
All Author List Ian S Zagon and Patricia J McLaughlin
Funding Agency and Grant Number
Funding Agency Grant Number
NIH (in part)
Philip Morris United States
Pennsylvania Department of Heath
Paul I and Anna E Shockey Family Foundation
Corresponding Author Patricia J McLaughlin, Professor, Department of Neural and Behavioral Sciences, Pennsylvania State University College of Medicine, MC-H109, 500 University Drive, Hershey, PA 17033, United States. pxm9@psu.edu
Key Words Enkephalins; DNA synthesis; Pancreatic adenocarcinoma; Opioids; Nude mice; Receptor transfection
Core Tip Opioid growth factor (OGF) biotherapy for human pancreatic cancer is based on inhibition of DNA synthesis by upregulation of cyclin-dependent inhibitory kinases. Preclinical studies using human pancreatic cancer cell lines have demonstrated that OGF interaction with its selective receptor OGF receptor (OGFr) is a physiological determinant of cell proliferation. Addition of OGF to standard chemotherapies enhances the efficacy of treatment. Studies in nude mice confirm that the OGF-OGFr axis regulates pancreatic cancer progression. Clinical trials using OGF for treatment of patients with unresectable pancreatic tumors reveal that OGF is a novel endogenous opioid that is safe, non-toxic, elicits negligible side effects and reduces pancreatic tumor size in persons who have failed other therapies.
Publish Date 2014-03-06 14:13
Citation Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: A review. World J Gastroenterol 2014; 20(9): 2218-2223
URL http://www.wjgnet.com/1007-9327/full/v20/i9/2218.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i9.2218
Full Article (PDF) WJG-20-2218.pdf
Full Article (Word) WJG-20-2218.doc
Manuscript File 5318-Review.doc
Answering Reviewers 5318-Answering reviewers.pdf
Copyright License Agreement 5318-Copyright agreement.pdf
Peer-review Report 5318-Peer review(s).pdf
Scientific Editor Work List 5318-Scientific editor work list.doc